These novel therapies , Semaglutide , represent a groundbreaking advancement in addressing obesity and potentially associated ailments . They all are categorized as GLP-1 receptor activators , meaning they function to emulate the endogenous GLP-1 substance , boosting insulin secretion and lowerin